In imatinib-resistant (IMR) CML cells, both the known oncogene H19 and its derived miR-675 were upregulated (Figures 1C,D) while the novel lncRNA, LNC000093, was downregulated (Figure 1I). This evidence concerns the gene H19 and chronic myelogenous leukemia, BCR-ABL1 positive.